Be the first to like this
OncBioMune LLC, a Baton Rouge, Louisiana based biotechnology company specializing in innovative cancer treatments, has proprietary rights to a breast cancer vaccine (patent #5,478,556 and patent application #20120282215) and prostate cancer vaccine (patent application #20120282216), and the targeted chemotherapy Paclitaxel- Gallium-Transferrin (patent application #20110190204). OncBioMune’s principals, Robert L. Elliott, M.D., Ph.D., Jonathan F. Head, Ph.D., have shown that OncBioMune’s technologies are safe, and utilize proven methods of treatment to provide optimal success for patients.
OncBioMune’s stand-alone technologies, utilizing transferrin transport technology and cancer vaccine technology, are applicable to other solid tumors, as well. The technologies of OncBioMune began with diseases of the breast as their foundation, but also provide platforms for prostate cancer and other solid tumors. The forecasted start up potential and the projected market for The Company’s products are optimal for success in the biotechnology industry.